GoodRx Holdings (GDRX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.08
- Surprise
- —
- Score today
- 4.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- GoodRx Joins Descope's Envoy Launch to Support AI Agent Authentication — fiscal.ai, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates GDRX Sell at 4.5/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate.
What supports the rating
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: prescription transactions offering (68.0%)
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.52
- Stop
- $3.28
The stock trades at 69.8× trailing but 9.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
GDRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.19B
- P/E (fwd)
- 9.9
- P/E (ttm)
- 69.8
- 52-week range
- $1.77–$3.89
- Off 52-week high
- 9.4%
- RSI (14)
- 57
- Volume vs avg
- 0.31×
- Score today
- 4.5/10